


2024
Updates in
Benign Hematology
Symposium

SUNDAY • OCTOBER 27

ZUCKERMAN RESEARCH CENTER
NEW YORK CITY



Memorial Sloan Kettering
Cancer Center



Overview

This symposium aims to deliver the latest updates in benign hematology, with a special emphasis on venous thromboembolism and anticoagulation.

The 2024 program will focus on three main areas:

- Current challenges in venous thromboembolism (VTE)
- Novel anticoagulants
- Thrombotic complications of clonal disorders

Key topics will include thrombophilia testing, the role of interventional radiology in VTE management, and challenging scenarios such as chronic thromboembolic pulmonary hypertension (CTEPH), refractory thrombosis, and splanchnic thrombosis. Additionally, faculty will review the reversal of direct oral anticoagulants, novel factor XI inhibitors, and unique challenges in the management of thrombosis and clonal disorders (e.g., PNH, myeloproliferative neoplasm, and clonal hematopoiesis).

Ample time will be allocated for Q&A and discussions after each presentations.

msk.org/BenignHemeUpdate



Target Audience & Format

The target audience for this symposium includes general medicine practitioners, hematologists/oncologists, intensivists, emergency medicine practitioners, primary care physicians, residents, fellows, advanced practice providers, and other healthcare professionals involved in the management and treatment of thrombotic and bleeding disorders.

Additionally, we're pleased to offer **complimentary registration for patients, advocates, and caregivers** to attend this program.

This symposium will be an **exclusively in-person event**, with no virtual attendance option available.

Learning Objectives

At the conclusion of this program, attendees will be able to:

- Provide guidance and updates on management of challenging thrombotic conditions including indications for thrombophilia testing, role of interventional radiology, management of refractory thrombosis, PNH, and anticoagulation in brain tumors.
- Summarize recent data on management of anticoagulant related hemorrhage and discuss emerging FXI inhibitors and their potential for improved safety profiles.
- Recognize the challenges in managing thrombo-hemorrhagic risks in patients with myeloproliferative neoplasms.



MSK Symposium Director



Jeffrey Zwicker, MD
Chief, Hematology Service

MSK Symposium Co-Director



Rekha Parameswaran, MD
Attending, Hematology Service

MSK Symposium Planning Committee

Kuo-Kai Chin, MD
Hematology-Oncology Fellow

Avi Leader, MD
Assistant Attending, Hematology Service

Jodi V. Mones, MD
Associate Program Director, Medical Oncology/Hematology
Fellowship, Hematology Track;
Associate Attending, Hematology Service

Michael Philbin, PhD
Patient Planner

Cara Scotti, PA
Advanced Practice Provider

Cy R. Wilkins, MD
Assistant Attending, Hematology Service

Invited Symposium faculty

Kenneth A. Bauer, MD

Professor of Medicine
Harvard Medical School
Beth Israel Deaconess Medical Center

Peter Gross, MD

Professor of Medicine
University of Toronto

Rushad Patell, MD

Assistant Professor of Medicine
Beth Israel Deaconess Medical Center

Deborah Siegal, MD, MSc, FRCPC

Associate Professor
University of Ottawa

MSK Symposium Faculty

Maly Fenelus, MD, MPH

Assistant Director, Clinical Hematology Laboratories;
Director, MSK Nassau Clinical Laboratory;
Assistant Attending
Department of Pathology and Laboratory Medicine

Ioanna Kosmidou, MD

Associate Attending, Cardiology Service

Raajit K. Rampal, MD, PhD

Director, Center for Hematologic Malignancies;
Director, Myeloproliferative Neoplasms Program;
Associate Attending, Leukemia Service

Jessica A. Wilcox, MD

Assistant Attending, Brain Tumor Service

Memorial Sloan Kettering Cancer Center adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all financial relationships with ineligible companies (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of the activity.

Schedule

SUNDAY • OCTOBER 27, 2024

8:15 AM Breakfast and Check-in

9:00 AM **Introductory Remarks**
Jeffrey Zwicker, MD

Challenges in Venous Thromboembolism

MODERATOR: Cy R. Wilkins, MD

9:05 AM **Approach to Anticoagulation in Brain Tumors**
Jessica A. Wilcox, MD

9:20 AM **The Challenge of Refractory Thrombosis**
Jeffrey Zwicker, MD

9:35 AM **Role of Interventional Radiology in Managing Venous Thromboembolism**
TBA

9:50 AM **Ins and Outs of Chronic Thromboembolic Pulmonary Hypertension**
TBA

10:05 AM **Hematologic Complications of Immunotherapy**
Jodi V. Mones, MD

10:20 AM **Thrombophilia Testing — Who, When, and Why**
Kenneth A. Bauer, MD

10:35 AM **PATIENT PERSPECTIVE**
Living with Venous Thromboembolism
Michael Philbin, PhD

10:50 AM Break

Topics in Anticoagulation

MODERATOR: Jeffrey Zwicker, MD

11:10 AM **Bleeding with Direct Oral Anticoagulants**
Deborah Siegal, MD, MSc, FRCPC

11:25 AM **Testing for Thrombophilia on Anticoagulants**
Maly Fenelus, MD, MPH

11:40 AM **Anticoagulation in Thrombocytopenic Patients**
Cy R. Wilkins, MD

11:55 AM **Thrombosis and Breast Cancer Therapy**
Avi Leader, MD

- 12:10 PM **Indications and Safety of Combined Antiplatelet and Anticoagulant Therapy**
Ioanna Kosmidou, MD
- 12:25 PM **Factor XI Inhibitors:
The Holy Grail of Anticoagulants?**
Peter Gross, MD
- 12:35 PM Lunch Break

Clonality and Thrombosis

MODERATOR: Rekha Parameswaran, MD

- 1:35 PM **Myeloproliferative Disease and Thrombosis**
Raajit K. Rampal, MD, PhD
- 1:50 PM **Clonal Hematopoiesis and Cardiovascular Disease**
TBA
- 2:05 PM **Peri-Operative Management of
Myeloproliferative Neoplasms**
Rushad Patell, MD
- 2:20 PM **Thrombosis and Paroxysmal Nocturnal
Hemoglobinuria**
Rekha Parameswaran, MD

2:35 PM **ROUNDTABLE DISCUSSION**
Myeloproliferative Neoplasms and Thrombosis

CASE PRESENTER Kuo-Kai Chin, MD
PANELISTS Kenneth A. Bauer, MD
Peter Gross, MD
Rushad Patell, MD
Raajit K. Rampal, MD, PhD

- 2:55 PM **Closing Remarks**
Rekha Parameswaran, MD
- 3:00 PM Adjournment



Accreditation

Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA Credit Designation Statement

Memorial Sloan Kettering Cancer Center designates this live activity for a maximum of **4.50 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC/CC Recognition Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:

4.50 Medical Knowledge MOC Points in the American Board of Internal Medicine's (**ABIM**) Maintenance of Certification Assessment Recognition program; and

4.50 Lifelong Learning (CME) credit towards the American Board of Pathology's (**ABPath**) Continuing Certification program.

It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM or ABPath MOC/CC credit.

An application for NCPD credits has been submitted.



Take advantage of our early registration rates,
available through September 14:

msk.org/BenignHemeSymposium

Registration Details

Included in registration, attendees will be offered continental breakfast, lunch, and refreshment breaks. Please contact cme@mskcc.org at least one week prior to the course if you have any special dietary requests or require any specific accommodations for joining us onsite.

Discounted registration is available for specific groups.

Visit the symposium website for additional details:

msk.org/BenignHemeSymposium

Course Fees	Early*	General
Physicians in Practice	\$250	\$300
Advanced Practice Providers	\$200	\$250
Nursing and Other Healthcare Professionals	\$150	\$200
Residents, Fellows, and Students	\$50	\$100
Industry Professionals**	\$525	\$525
MSK Employees, Patients, Advocates, and Caregivers	Complimentary	

*Apply promotion code **TRMEARL24** during registration to take advantage of early discounted rates. Offer valid through September 14, 2024.

An “industry professional**” is defined as any individual, regardless of their profession type (such as MDs, PhDs, APPs, RNs, etc.) that is employed by an ineligible company.



Memorial Sloan Kettering
Cancer Center